CN108982184B - Method for preventing coagulation during blood test - Google Patents
Method for preventing coagulation during blood test Download PDFInfo
- Publication number
- CN108982184B CN108982184B CN201810934156.5A CN201810934156A CN108982184B CN 108982184 B CN108982184 B CN 108982184B CN 201810934156 A CN201810934156 A CN 201810934156A CN 108982184 B CN108982184 B CN 108982184B
- Authority
- CN
- China
- Prior art keywords
- anticoagulant
- blood
- graphene quantum
- preparing
- quantum dot
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention discloses a method for preventing coagulation during blood test, which comprises the following manufacturing steps: the method comprises the following steps: preparing an anticoagulant A: preparing disodium ethylene diamine tetraacetate and normal saline according to the proportion of 1:2 to generate an anticoagulant A; preparing an anticoagulant B: preparing heparin and normal saline according to the proportion of 1:8-10 to generate an anticoagulant B; preparing an anticoagulant C: preparing sodium citrate and citrate according to the ratio of 1:1.5 to generate an anticoagulant C; step two: and (4) collecting fresh blood. The anticoagulant agent generated by the disodium ethylene diamine tetraacetate, the heparin, the sodium citrate, the citrate or the normal saline can effectively prevent the blood from coagulating in a short time, not only changes the property of the blood, but also influences the storage and the injection of the blood.
Description
Technical Field
The invention relates to the field of blood detection, in particular to a method for preventing coagulation during blood test.
Background
Blood is an opaque red liquid flowing in the heart and blood vessels, and mainly contains plasma, blood cells, and genetic materials (chromosomes and genes), and belongs to connective tissues, i.e., the tissue level in the living system. Blood contains various nutrients such as inorganic salts, oxygen, cellular metabolites, hormones, enzymes, antibodies, etc., and has effects of nourishing tissues, regulating organ activities, and protecting against harmful substances. Blood stores human health information, and many diseases require blood tests, including genetic diseases.
When carrying out blood detection, need draw and save blood earlier, because there is serum in the blood, can make blood take place to solidify in the regulation time, but when a large amount of personnel took the blood to draw blood to test, because medical staff detects the plenty of time that takes to blood, so can make the blood of drawing carry out the storage, but because the test time length differs, can make blood save time greatly increased to cause blood to take place to solidify, changed the attribute of blood, thereby cause the influence to blood test result. Therefore, it is necessary to develop a method for preventing coagulation in blood test to solve the above problems.
Disclosure of Invention
To overcome the disadvantages and shortcomings of the prior art, it is an object of the present invention to provide a method for preventing coagulation during blood test, which greatly increases the storage time of blood.
In order to achieve the purpose, the invention provides the following technical scheme:
a method of preventing clotting in testing blood comprising the steps of: fresh blood collection, namely, collecting fresh blood in a blood bank; injecting the fresh blood collected in the step I into a test tube, then injecting an anticoagulant into the test tube, wherein the injection amount of the anticoagulant is 5-8 wt% of the blood amount of the test tube, and after injection, storing the test tube in an aseptic environment at the temperature of 3-5 ℃; and thirdly, after the anticoagulant is injected, oscillating to fully fuse, standing the test tube, and observing the coagulation condition in the test tube.
The anticoagulant comprises any one of anticoagulant A, anticoagulant B, anticoagulant C and anticoagulant D;
the preparation method of the anticoagulant A comprises the following steps: preparing disodium ethylene diamine tetraacetate and normal saline according to the proportion of 1:2 to generate an anticoagulant A;
the preparation method of the anticoagulant B comprises the following steps: preparing heparin and normal saline according to the proportion of 1:8-10 to generate an anticoagulant B;
the preparation method of the anticoagulant C comprises the following steps: preparing sodium citrate and citrate according to the ratio of 1:1.5 to generate an anticoagulant C;
the anticoagulant D is physiological saline;
the preparation method comprises the following steps of preparing a magnetic composite graphene quantum dot, wherein the magnetic composite graphene quantum dot is 1/90 in mass ratio to an anticoagulant A, the magnetic composite graphene quantum dot comprises a graphene quantum dot and nano ferroferric oxide physically adsorbed on the graphene quantum dot, and the magnetic composite graphene quantum dot is prepared through the following steps:
(1) reacting pyrene with nitric acid at the temperature of 95 ℃ to prepare trinitropyrene, then re-suspending the trinitropyrene by using ammonia water, after ultrasonic reaction, adding the reacted mixture into a reaction kettle, and preparing aminated graphene quantum dots by hydrothermal reaction at the temperature of 175 ℃;
(2) and physically adsorbing ferroferric oxide nano powder with the particle size of 20-40 nanometers on the graphene quantum dots through a magnetic stirring mechanism.
The invention has the technical effects and advantages that:
1. the anticoagulant agent generated by the disodium ethylene diamine tetraacetate, the heparin, the sodium citrate, the citrate or the normal saline can effectively prevent the blood from coagulating in a short time, not only changes the property of the blood, but also influences the storage and the injection of the blood;
2. through comparing each group of anticoagulants in the same environmental direction, the effect of preventing blood coagulation of each anticoagulant in different time is compared, and the anticoagulant selection can be carried out according to the mode of storing blood for a short time by referring to the blood without any anticoagulant, so that the anticoagulant prevention effect that the selected anticoagulant does not reach the set time is avoided.
3. Through adding the compound graphite alkene quantum dot of magnetism, this compound graphite alkene quantum dot of magnetism is including two important components, wherein the graphite alkene quantum dot of theme part itself does not contain any poisonous heavy metal element, possess excellent environment friendship nature and biocompatibility, and easily surface functionalization modification, be convenient for get into the blood that awaits measuring, form stable biocompatibility, and magnetism nanometer ferroferric oxide, can with the red blood cell interact that has little magnetism in the blood, thereby make red blood cell mutual separation and keep the stable state, the anticoagulation effect has greatly been improved.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
A method of preventing clotting in testing blood comprising the following manufacturing steps:
the method comprises the following steps:
preparing an anticoagulant A: preparing disodium ethylene diamine tetraacetate and normal saline according to the proportion of 1:2 to generate an anticoagulant A;
preparing an anticoagulant B: preparing heparin and normal saline according to the proportion of 1:8 to generate an anticoagulant B;
preparing an anticoagulant C: preparing sodium citrate and citrate according to the ratio of 1:1.5 to generate an anticoagulant C;
preparing an anticoagulant D: the anticoagulant D is formed by normal saline;
the preparation method comprises the following steps of preparing a magnetic composite graphene quantum dot, wherein the magnetic composite graphene quantum dot is 1/90 in mass ratio to an anticoagulant A, the magnetic composite graphene quantum dot comprises a graphene quantum dot and nano ferroferric oxide physically adsorbed on the graphene quantum dot, and the magnetic composite graphene quantum dot is prepared through the following steps:
(1) reacting pyrene with nitric acid at the temperature of 95 ℃ to prepare trinitropyrene, then re-suspending the trinitropyrene by using ammonia water, after ultrasonic reaction, adding the reacted mixture into a reaction kettle, and preparing aminated graphene quantum dots by hydrothermal reaction at the temperature of 175 ℃;
(2) and physically adsorbing ferroferric oxide nano powder with the particle size of 20-40 nanometers on the graphene quantum dots through a magnetic stirring mechanism.
Step two: collecting fresh blood, namely collecting fresh blood in a blood bank;
step three: injecting a proper amount of fresh blood extracted in the step two into 5 groups of test tubes, wherein the fresh blood is respectively marked as I, II, III, IV and V, then respectively injecting the anticoagulant prepared in the step one into the test tubes I-IV, wherein the injection amount of the anticoagulant is 5wt% of the blood amount of the test tubes, the test tubes need to be oscillated during injection to ensure that the anticoagulant is fully fused with the blood, and after injection, the test tubes are stored in a sterile environment at the temperature of 3 ℃;
step four: after the anticoagulant in each group is injected, the test tubes are stood for 1 hour, then the environment of each group of test tubes is kept to be the same, and the blood coagulation condition in each group of test tubes is observed.
Example 2
A method of preventing clotting in testing blood comprising the following manufacturing steps:
the method comprises the following steps:
preparing an anticoagulant A: preparing disodium ethylene diamine tetraacetate and normal saline according to the proportion of 1:2 to generate an anticoagulant A;
preparing an anticoagulant B: preparing heparin and normal saline according to the proportion of 1:8 to generate an anticoagulant B;
preparing an anticoagulant C: preparing sodium citrate and citrate according to the ratio of 1:1.5 to generate an anticoagulant C;
preparing an anticoagulant D: the anticoagulant D is formed by normal saline;
the preparation method comprises the following steps of preparing a magnetic composite graphene quantum dot, wherein the magnetic composite graphene quantum dot is 1/90 in mass ratio to an anticoagulant A, the magnetic composite graphene quantum dot comprises a graphene quantum dot and nano ferroferric oxide physically adsorbed on the graphene quantum dot, and the magnetic composite graphene quantum dot is prepared through the following steps:
(1) reacting pyrene with nitric acid at the temperature of 95 ℃ to prepare trinitropyrene, then re-suspending the trinitropyrene by using ammonia water, after ultrasonic reaction, adding the reacted mixture into a reaction kettle, and preparing aminated graphene quantum dots by hydrothermal reaction at the temperature of 175 ℃;
(2) and physically adsorbing ferroferric oxide nano powder with the particle size of 20-40 nanometers on the graphene quantum dots through a magnetic stirring mechanism.
Step two: fresh blood in a blood bank is adopted;
step three: injecting a proper amount of fresh blood extracted in the step two into 5 groups of test tubes, wherein the fresh blood is respectively marked as I, II, III, IV and V, then respectively injecting the anticoagulant prepared in the step one into the test tubes I-IV, wherein the injection amount of the anticoagulant is 5wt% of the blood amount of the test tubes, the test tubes need to be vibrated during injection to ensure that the anticoagulant is fully fused with the blood, and after injection, the test tubes are stored in a sterile environment at the temperature of 3 ℃;
step four: after the anticoagulant in each group is injected, the test tubes are stood for 2 hours, then the environment of each group of test tubes is kept to be the same, and the blood coagulation condition in each group of test tubes is observed.
Example 3
A method of preventing clotting in testing blood comprising the following manufacturing steps:
the method comprises the following steps:
preparing an anticoagulant A: preparing disodium ethylene diamine tetraacetate and normal saline according to the proportion of 1:2 to generate an anticoagulant A;
preparing an anticoagulant B: preparing heparin and normal saline according to the proportion of 1:8 to generate an anticoagulant B;
preparing an anticoagulant C: preparing sodium citrate and citrate according to the ratio of 1:1.5 to generate an anticoagulant C;
preparing an anticoagulant D: the anticoagulant D is formed by normal saline;
the preparation method comprises the following steps of preparing a magnetic composite graphene quantum dot, wherein the magnetic composite graphene quantum dot is 1/90 in mass ratio to an anticoagulant A, the magnetic composite graphene quantum dot comprises a graphene quantum dot and nano ferroferric oxide physically adsorbed on the graphene quantum dot, and the magnetic composite graphene quantum dot is prepared through the following steps:
(1) reacting pyrene with nitric acid at the temperature of 95 ℃ to prepare trinitropyrene, then re-suspending the trinitropyrene by using ammonia water, after ultrasonic reaction, adding the reacted mixture into a reaction kettle, and preparing aminated graphene quantum dots by hydrothermal reaction at the temperature of 175 ℃;
(2) and physically adsorbing ferroferric oxide nano powder with the particle size of 20-40 nanometers on the graphene quantum dots through a magnetic stirring mechanism.
Step two: collecting fresh blood: fresh blood in a blood bank is adopted; (ii) a
Step three: injecting a proper amount of fresh blood extracted in the step two into 5 groups of test tubes, wherein the fresh blood is respectively marked as I, II, III, IV and V, then respectively injecting the anticoagulant prepared in the step one into the test tubes I-IV, wherein the injection amount of the anticoagulant is 5wt% of the blood amount of the test tubes, the test tubes need to be vibrated during injection to ensure that the anticoagulant is fully fused with the blood, and after injection, the test tubes are stored in a sterile environment at the temperature of 3 ℃;
step four: after the anticoagulant in each group is injected, the test tubes are stood for 3 hours from the first to the fifth, then the environment of each group of test tubes is kept to be the same, and the blood coagulation condition in each group of test tubes is observed.
With reference to examples 1-3, the blood clotting in each set of tubes was observed and the following table was prepared:
by the above tableIt is known that when disodium ethylenediaminetetraacetate or a mixed liquid of heparin and physiological saline, sodium citrate and citrate are added to blood within 35 minutes, coagulation of blood does not occur, and when disodium ethylenediaminetetraacetate or a mixed liquid of heparin and physiological saline, sodium citrate and citrate are added to blood within 45 minutes, coagulation of blood does not occurAdding disodium ethylene diamine tetraacetateOr a mixed liquid of heparin and physiological saline, the blood in the test tube does not coagulate.
Finally, it should be noted that: although the present invention has been described in detail with reference to the foregoing embodiments, it will be apparent to those skilled in the art that modifications may be made to the embodiments or portions thereof without departing from the spirit and scope of the invention.
Claims (1)
1. A method for preventing clotting in testing blood, comprising the steps of: fresh blood is collected; injecting the fresh blood extracted in the step one into a test tube, then injecting an anticoagulant into the test tube, wherein the injection amount of the anticoagulant is 5-8 wt% of the blood amount of the test tube, and after injection, storing the test tube in an aseptic environment at the temperature of 3-5 ℃; thirdly, after the anticoagulant is injected, oscillating and fully fusing, standing the test tube, and observing the coagulation condition in the test tube;
the anticoagulant comprises anticoagulant A; the preparation method of the anticoagulant A comprises the following steps: preparing disodium ethylene diamine tetraacetate and normal saline according to the proportion of 1:2 to generate an anticoagulant A;
the preparation method comprises the following steps of preparing a magnetic composite graphene quantum dot, wherein the magnetic composite graphene quantum dot is 1/90 in mass ratio to an anticoagulant A, the magnetic composite graphene quantum dot comprises a graphene quantum dot and nano ferroferric oxide physically adsorbed on the graphene quantum dot, and the magnetic composite graphene quantum dot is prepared through the following steps:
(1) reacting pyrene with nitric acid at the temperature of 95 ℃ to prepare trinitropyrene, then re-suspending the trinitropyrene by using ammonia water, after ultrasonic reaction, adding the reacted mixture into a reaction kettle, and preparing aminated graphene quantum dots by hydrothermal reaction at the temperature of 175 ℃;
(2) and physically adsorbing ferroferric oxide nano powder with the particle size of 20-40 nanometers on the graphene quantum dots through a magnetic stirring mechanism.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810934156.5A CN108982184B (en) | 2018-08-16 | 2018-08-16 | Method for preventing coagulation during blood test |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810934156.5A CN108982184B (en) | 2018-08-16 | 2018-08-16 | Method for preventing coagulation during blood test |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108982184A CN108982184A (en) | 2018-12-11 |
| CN108982184B true CN108982184B (en) | 2021-03-16 |
Family
ID=64553220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810934156.5A Active CN108982184B (en) | 2018-08-16 | 2018-08-16 | Method for preventing coagulation during blood test |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108982184B (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102313813B (en) * | 2008-05-20 | 2014-01-15 | 北京莱尔生物医药科技有限公司 | Integration method for enriching and detecting rare cells from biological fluid samples |
| CN101587043B (en) * | 2008-05-20 | 2013-10-02 | 北京莱尔生物医药科技有限公司 | Integrated method for enriching and detecting rare cell in biological fluid sample |
| US20100111845A1 (en) * | 2008-10-31 | 2010-05-06 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Compositions and methods for therapeutic delivery with frozen particles |
-
2018
- 2018-08-16 CN CN201810934156.5A patent/CN108982184B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN108982184A (en) | 2018-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhuang et al. | Biomimetic nanoemulsions for oxygen delivery in vivo | |
| Liu et al. | Erythrocyte–platelet hybrid membranes coating polypyrrol nanoparticles for enhanced delivery and photothermal therapy | |
| Shi et al. | (Carboxymethyl) chitosan-modified superparamagnetic iron oxide nanoparticles for magnetic resonance imaging of stem cells | |
| CN106148315A (en) | A kind of CTC based on chitin nanometer capture and purification substrate and preparation method thereof | |
| CN106366426B (en) | A kind of platelet rich plasma extraction and the separation gel system purified and preparation method thereof | |
| CN102766616A (en) | Thrombin isolated from blood and blood fractions | |
| CN103463565B (en) | Zedoary oil injection and preparation method thereof | |
| Xu et al. | Preparation of electrospray ALG/PDA–PVP nanocomposites and their application in cancer therapy | |
| CN108743615B (en) | Nano magnetic particle wrapped by erythrocyte membrane, preparation method and application thereof | |
| CN101785764A (en) | Method for improving blood compatibility of microcapsule | |
| CN109276577A (en) | A kind of nitric oxide Nanometer composite hydrogel and its preparation method and application | |
| MacCuaig et al. | Toxicity assessment of mesoporous silica nanoparticles upon intravenous injection in mice: implications for drug delivery | |
| Han et al. | Blood compatibility of polyamidoamine dendrimers and erythrocyte protection | |
| CN108982184B (en) | Method for preventing coagulation during blood test | |
| CN1733298B (en) | Microcapsule type blood substitute based on hemoglobin and process for preparing the same | |
| CN103948946A (en) | Method for preparing supramolecular nano-micelles for temperature response magnetic resonance imaging | |
| CN105037820A (en) | Chitosan low-temperature hydrogel and preparation method thereof | |
| Piras et al. | pH-Responsive carboxymethylcellulose nanoparticles for 68Ga-WBC labeling in PET imaging | |
| CN109223827A (en) | Application of the water-soluble fullerene structure in the drug of preparation treatment pulmonary fibrosis | |
| Raheem | Study effect of silver nanoparticles on some blood parameters in rabbits | |
| CN105456197A (en) | Preparation method of hydrogel nanoparticles capable of adsorbing melittin and detection method of affinity of hydrogel nanoparticles | |
| Xu et al. | A novel artificial red blood cell substitute: grafted starch-encapsulated hemoglobin | |
| CN102875733B (en) | Nanoparticles with epicyte-imitated structure and preparation method thereof | |
| CN103211762A (en) | Novel diagnosis and treatment integrated hybridization micelle and preparation method thereof | |
| CN110585448B (en) | Nano diagnosis and treatment agent for acute kidney injury and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |